Cargando…

Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies

In Japan, hepatocellular carcinoma (HCC) is a leading cause of cancer mortality and hepatitis C virus infection is a major cause of HCC. We conducted a systematic review and meta-analysis of published studies evaluating patient response to antiviral therapy for chronic hepatitis C on the risk of HCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamagiwa, Yoko, Tanaka, Keitaro, Matsuo, Keitaro, Wada, Keiko, Lin, Yingsong, Sugawara, Yumi, Mizoue, Tetsuya, Sawada, Norie, Takimoto, Hidemi, Ito, Hidemi, Kitamura, Tetsuhisa, Sakata, Ritsu, Kimura, Takashi, Tanaka, Shiori, Inoue, Manami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977913/
https://www.ncbi.nlm.nih.gov/pubmed/36859564
http://dx.doi.org/10.1038/s41598-023-30467-5
_version_ 1784899398091669504
author Yamagiwa, Yoko
Tanaka, Keitaro
Matsuo, Keitaro
Wada, Keiko
Lin, Yingsong
Sugawara, Yumi
Mizoue, Tetsuya
Sawada, Norie
Takimoto, Hidemi
Ito, Hidemi
Kitamura, Tetsuhisa
Sakata, Ritsu
Kimura, Takashi
Tanaka, Shiori
Inoue, Manami
author_facet Yamagiwa, Yoko
Tanaka, Keitaro
Matsuo, Keitaro
Wada, Keiko
Lin, Yingsong
Sugawara, Yumi
Mizoue, Tetsuya
Sawada, Norie
Takimoto, Hidemi
Ito, Hidemi
Kitamura, Tetsuhisa
Sakata, Ritsu
Kimura, Takashi
Tanaka, Shiori
Inoue, Manami
author_sort Yamagiwa, Yoko
collection PubMed
description In Japan, hepatocellular carcinoma (HCC) is a leading cause of cancer mortality and hepatitis C virus infection is a major cause of HCC. We conducted a systematic review and meta-analysis of published studies evaluating patient response to antiviral therapy for chronic hepatitis C on the risk of HCC occurrence in Japan. Articles were searched using terms determined a priori through PubMed, screened by title and abstract, and selected by full-text assessment according to criteria determined a priori, including HCC occurrence in response to interferon (IFN)-based or IFN-free therapy, Japanese study, and 2 or more years of follow-up. We excluded studies on HCC recurrence. We calculated the pooled estimate of the crude incidence rate ratio with data from the selected studies using the person-years method with Poisson regression model and pooled estimate of the hazard ratio adjusted for potential confounders reported by the studies using a random effects model. A total of 26 studies were identified, all of which examined only IFN-based therapy as a result of the selection process. The pooled estimate (95% confidence interval [CI]) of 25 studies was 0.37 (0.33–0.43) for sustained virologic response (SVR) and 1.70 (1.61–1.80) for non-SVR for the HCC incidence rate per 100 person-years, and 0.22 (0.19–0.26) for the incidence rate ratio (SVR vs. non-SVR). The pooled estimate of the hazard ratio (95% CI) of HCC incidence adjusted for potential confounders of 8 studies was 0.25 (0.19–0.34). SVR to interferon therapy for chronic hepatitis C reduces the risk of HCC occurrence.
format Online
Article
Text
id pubmed-9977913
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-99779132023-03-03 Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies Yamagiwa, Yoko Tanaka, Keitaro Matsuo, Keitaro Wada, Keiko Lin, Yingsong Sugawara, Yumi Mizoue, Tetsuya Sawada, Norie Takimoto, Hidemi Ito, Hidemi Kitamura, Tetsuhisa Sakata, Ritsu Kimura, Takashi Tanaka, Shiori Inoue, Manami Sci Rep Article In Japan, hepatocellular carcinoma (HCC) is a leading cause of cancer mortality and hepatitis C virus infection is a major cause of HCC. We conducted a systematic review and meta-analysis of published studies evaluating patient response to antiviral therapy for chronic hepatitis C on the risk of HCC occurrence in Japan. Articles were searched using terms determined a priori through PubMed, screened by title and abstract, and selected by full-text assessment according to criteria determined a priori, including HCC occurrence in response to interferon (IFN)-based or IFN-free therapy, Japanese study, and 2 or more years of follow-up. We excluded studies on HCC recurrence. We calculated the pooled estimate of the crude incidence rate ratio with data from the selected studies using the person-years method with Poisson regression model and pooled estimate of the hazard ratio adjusted for potential confounders reported by the studies using a random effects model. A total of 26 studies were identified, all of which examined only IFN-based therapy as a result of the selection process. The pooled estimate (95% confidence interval [CI]) of 25 studies was 0.37 (0.33–0.43) for sustained virologic response (SVR) and 1.70 (1.61–1.80) for non-SVR for the HCC incidence rate per 100 person-years, and 0.22 (0.19–0.26) for the incidence rate ratio (SVR vs. non-SVR). The pooled estimate of the hazard ratio (95% CI) of HCC incidence adjusted for potential confounders of 8 studies was 0.25 (0.19–0.34). SVR to interferon therapy for chronic hepatitis C reduces the risk of HCC occurrence. Nature Publishing Group UK 2023-03-01 /pmc/articles/PMC9977913/ /pubmed/36859564 http://dx.doi.org/10.1038/s41598-023-30467-5 Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Yamagiwa, Yoko
Tanaka, Keitaro
Matsuo, Keitaro
Wada, Keiko
Lin, Yingsong
Sugawara, Yumi
Mizoue, Tetsuya
Sawada, Norie
Takimoto, Hidemi
Ito, Hidemi
Kitamura, Tetsuhisa
Sakata, Ritsu
Kimura, Takashi
Tanaka, Shiori
Inoue, Manami
Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies
title Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies
title_full Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies
title_fullStr Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies
title_full_unstemmed Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies
title_short Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies
title_sort response to antiviral therapy for chronic hepatitis c and risk of hepatocellular carcinoma occurrence in japan: a systematic review and meta-analysis of observational studies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977913/
https://www.ncbi.nlm.nih.gov/pubmed/36859564
http://dx.doi.org/10.1038/s41598-023-30467-5
work_keys_str_mv AT yamagiwayoko responsetoantiviraltherapyforchronichepatitiscandriskofhepatocellularcarcinomaoccurrenceinjapanasystematicreviewandmetaanalysisofobservationalstudies
AT tanakakeitaro responsetoantiviraltherapyforchronichepatitiscandriskofhepatocellularcarcinomaoccurrenceinjapanasystematicreviewandmetaanalysisofobservationalstudies
AT matsuokeitaro responsetoantiviraltherapyforchronichepatitiscandriskofhepatocellularcarcinomaoccurrenceinjapanasystematicreviewandmetaanalysisofobservationalstudies
AT wadakeiko responsetoantiviraltherapyforchronichepatitiscandriskofhepatocellularcarcinomaoccurrenceinjapanasystematicreviewandmetaanalysisofobservationalstudies
AT linyingsong responsetoantiviraltherapyforchronichepatitiscandriskofhepatocellularcarcinomaoccurrenceinjapanasystematicreviewandmetaanalysisofobservationalstudies
AT sugawarayumi responsetoantiviraltherapyforchronichepatitiscandriskofhepatocellularcarcinomaoccurrenceinjapanasystematicreviewandmetaanalysisofobservationalstudies
AT mizouetetsuya responsetoantiviraltherapyforchronichepatitiscandriskofhepatocellularcarcinomaoccurrenceinjapanasystematicreviewandmetaanalysisofobservationalstudies
AT sawadanorie responsetoantiviraltherapyforchronichepatitiscandriskofhepatocellularcarcinomaoccurrenceinjapanasystematicreviewandmetaanalysisofobservationalstudies
AT takimotohidemi responsetoantiviraltherapyforchronichepatitiscandriskofhepatocellularcarcinomaoccurrenceinjapanasystematicreviewandmetaanalysisofobservationalstudies
AT itohidemi responsetoantiviraltherapyforchronichepatitiscandriskofhepatocellularcarcinomaoccurrenceinjapanasystematicreviewandmetaanalysisofobservationalstudies
AT kitamuratetsuhisa responsetoantiviraltherapyforchronichepatitiscandriskofhepatocellularcarcinomaoccurrenceinjapanasystematicreviewandmetaanalysisofobservationalstudies
AT sakataritsu responsetoantiviraltherapyforchronichepatitiscandriskofhepatocellularcarcinomaoccurrenceinjapanasystematicreviewandmetaanalysisofobservationalstudies
AT kimuratakashi responsetoantiviraltherapyforchronichepatitiscandriskofhepatocellularcarcinomaoccurrenceinjapanasystematicreviewandmetaanalysisofobservationalstudies
AT tanakashiori responsetoantiviraltherapyforchronichepatitiscandriskofhepatocellularcarcinomaoccurrenceinjapanasystematicreviewandmetaanalysisofobservationalstudies
AT inouemanami responsetoantiviraltherapyforchronichepatitiscandriskofhepatocellularcarcinomaoccurrenceinjapanasystematicreviewandmetaanalysisofobservationalstudies
AT responsetoantiviraltherapyforchronichepatitiscandriskofhepatocellularcarcinomaoccurrenceinjapanasystematicreviewandmetaanalysisofobservationalstudies